Relationship Between COVID-19 Cases and Vaccination Rates in New York State Counties

Abstract

Introduction

Vaccines against SARS-CoV-2 have been developed with unprecedented speed. The phased introduction of vaccines may be serving to offset the impact of new viral variants and policy relaxation. In order to assess the impact of vaccination, we examined a snapshot of vaccination rates across counties in a single state, at a single time point, comparing them with population-adjusted case counts.

Methods

We calculated descriptive statistics and bivariate correlations for vaccination rates and cases across counties in New York State (NYS). We conducted a linear regression using cases/100K population per NYS county, frozen at a single snapshot in time, as the outcome variable, predicted by percentage of each county’s population (completed series/two doses), controlling for county population.

Results

Percentages with one dose and with two doses were highly correlated (r=.935, P<.001) with one another. Both the one dose and two dose z rates were negatively correlated with cases per 100K population (not significant). Population size was strongly correlated with cases per 100K (r=.715, P<.001). The two-dose vaccination rate was a significant negative predictor of cases per 100K population in NYS counties (β= −.866, P=.031), with each percentage point of completed vaccination nearly equating to one case less in the daily count when controlling for county population size (β =2.732, P<.001).

Conclusion

While variants may impact vaccine effectiveness, current vaccination efforts are helping forestall some cases in NYS. Widespread vaccination is still an important goal. Primary care providers, public officials, and public health scientists should continue to urgently promote and support vaccination efforts.

Introduction

The novel 2019 coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus was declared a pandemic by the World Health Organization in March 2020.¹ The virus is spread primarily through person-to-person contact,² and both airborne transmission and spread by asymptomatic individuals are likely pathways to transmit SARS-CoV-2.^3,4 COVID-19 has been responsible for over 32 million cases and over 572,000 deaths in the United States, numbers which continue to grow each day.⁴

Vaccines against SARS-CoV-2 have been developed with unprecedented speed. Three are presently in use in the United States, including two that use a messenger RNA (mRNA) vector, and one that relies upon an adenovirus vector.^5–8 Based on the limited availability of the supply of COVID-19 vaccine in the United States, the Centers for Disease Control and Prevention (CDC) provided recommendations for phased vaccination, prioritizing health care workers as well as those living and working in long-term care facilities. As supplies increased, eligibility expanded to other frontline essential workers, followed by those over the age of 65 and younger individuals with high-risk comorbidities.¹⁰ In New York State (NYS), the final groups to become eligible were all other essential workers, followed by healthy adults.^10,11 All individuals aged 16 years and over subsequently became eligible to receive the vaccine in NYS (April 6, 2021) and across the United States (April 19, 2021).^12,13

In late March 2021, cases of COVID-19 began to rise in NYS and across the United States, representing a third spike in NYS¹⁴ and a fourth for the United States as a whole.¹⁵ A combination of new viral variants,¹⁶ combined with premature relaxation of social distancing measures¹⁷ that had proved effective earlier in the pandemic,¹⁸ likely contributed to the latest spike. The phased introduction of vaccines, however, may be serving to offset the impact of new viral variants and policy relaxation. Several reports from the CDC have noted disparities in vaccination coverage by geography and population, noting disparities across the rural-urban divide,¹⁹ by social vulnerability,²⁰ and across county borders.²⁰ However, to date, we have seen no studies that directly examine the relationship between vaccination and test positivity rates for COVID-19 at the county level. In order to assess the impact of vaccination, we examined a snapshot of vaccination rates across counties in a single state, at a single time point, comparing them with population-adjusted case counts.

Methods

The NYS Department of Health shares vaccination rates per county through the NYS COVID-19 Vaccine Tracker tool, using data reported to the NYS Immunization Information System and the New York City Citywide Immunization Registry.²¹ This online resource is updated daily and includes the number of vaccinated individuals per county, including those who have received at least one vaccine dose and those who have received a completed vaccine series. COVID-19 case rates at the county level are also widely available for all states including NYS, via a cases-per-100K population variable based on a 7-day average that is publicly available from Johns Hopkins University.²² We extracted NYS data from both sources to calculate the relationship between vaccination and case rates, and to incorporate analysis of county population, as well. We created the data set for analysis using information available on March 31, 2021.

We calculated descriptive statistics and bivariate correlations for vaccination rates (percent of population with one dose, and with two doses or completed series) and cases across the 62 counties of NYS. We then conducted the core analysis as a linear regression, using cases/100K population per NYS county, frozen at a single snapshot in time (March 31), as the outcome variable, predicted by percentage of each county’s population (completed series/two doses), controlling for county population. We conducted all analyses using IBM SPSS Statistics v 27. As only aggregated public data were used, this project did not constitute human subjects research.

Results

NYS counties had a mean of 29.7 cases per 100K residents (range: 6.2–108.3). On March 31, NYS had vaccinated approximately 31% of its residents (mean county percent: 30.98, range: 21.8%–57.4%) with one dose of vaccine, and a mean of 18% (mean county percent: 18.12, range: 12.3% – 41.8%) of residents with a full vaccination course (Table 1).

Table 1.

Rates of COVID-19 Cases per 100,000 Residents, and Rates of Vaccination, Calculated for New York State Counties (N=62) on March 31, 2021

	Minimum	Maximum	Mean (SD)
Cases/100K	6.20	108.30	29.66 (21.3862)
Population %: one dose	21.76%	57.42%	30.98% (5.76%)
Population %: two doses	12.27%	41.79%	18.12% (4.81%)

Percentages with one dose and with two doses were highly correlated (r=.935, P<.001) with one another. Both the one-dose and two-dose rates were negatively correlated with cases per 100K population, but the association was not significant at the .05 level in bivariate testing. Population size was strongly correlated with cases per 100K (r=.715, P<.001). Further detail is provided in Table 2.

Table 2.

Pearson Correlation Coefficients (P) for 62 New York State Counties

	Pct 1 Dose	Pct 2 Dose	Population	Cases/100K
Population %: one dose	1.00	0.935 (P<.001)	−0.108 (P=.404)	−0.226 (P=.078)
Population %: two doses	0.935 (P<.001)	1.00	−0.096 (P=.458)	−0.096 (P=.458)
Total population	−0.108 (P=.404)	−0.096 (P=0.458)	1.00	0.715 (P<.001)
Cases/100K	−0.226 (P=.078)	−0.096 (P=0.458)	0.715 (P<.001)	1.00

The two-dose vaccination rate was a significant negative predictor of cases per 100K population in NYS Counties (β= −.866, P=.031), with each percentage point of completed vaccination nearly equating to one case less in the daily count on March 31, when controlling for county population size (β =2.732, P<.001; Table 3).

Table 3.

Estimation of Effect of Rate of Full Vaccination on COVID-19 Cases per 100k County Population in New York State on March 31, 2021, Controlling for Population Size, Via Ordinary Least Squares Regression

Variable	β	t(P)	CI
(Constant)	36.74	4.90 (<.001)	21.72 – 51.75
Population %: two doses	−0.87	−2.21 (.031)	−1.65 – −0.08
Population (100K)	2.73	7.92 (<.001)	2.04 – 3.42

Conclusion

While variants of concern (B.1.1.7/Alpha, P.1/Gamma, B.1.351/Beta, B.1.167.2/Delta) may impact vaccine effectiveness, current vaccination efforts appear to have nonetheless helped forestall some cases in New York State during spring 2021. Despite any concerns about vaccine effectiveness in the face of emerging variants, widespread vaccination, with those vaccines that are currently available, is still an important goal. Population levels, and possibly by implication, population density, are also related to case emergence. Large gatherings and business openings may still be risky. This underscores the need to offset derestriction with robust vaccination efforts.

This study faced several limitations. First, data series of vaccination rates were not readily available, and many data relevant to COVID-19 were difficult to acquire. This study was performed with a snapshot of 1 day of data. Nevertheless, we strongly believe a time series would reveal the same information. There are also reporting errors or discrepancies as data are reported from counties, to states, and then aggregated in public reporting mechanisms. We believe these data are robust enough to be used in the analysis as presented. Also, the role of COVID-19 variants was not considered in this study. Public data on variant tracking are extremely limited, both by limited reporting and by the existence of good variant tracking itself. It is also important to note that, as a cross-sectional, single-day, retrospective, observational study of association, we cannot establish a causal link between vaccination rates and test positivity per county with this analysis. It is, however, highly suggestive of the importance of vaccination.

Limitations aside, we believe this study provides additional evidence for the effectiveness of the current vaccines available in the United States in stemming the tide of emergent COVID-19 infections. Even though the Delta variant appears to evade both natural and vaccine-induced immunity to some extent, current vaccines in the United States are still effective at preventing serious illness and hospitalization.^23,24 Future research is already underway across the world assessing the effectiveness of vaccines against new variants, and we urge that such research continue across the spectrum, from the serological to the population level. Meanwhile, primary care providers, public officials, and public health scientists should continue to urgently promote and support vaccination efforts.